Cancer biology research highlighted the role of BRCA1/2 mutations and homologous recombination deficiency (HRD), which opened the field for targeted therapies such as poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). This evidence concerns the gene BRCA1 and cancer.